Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tetramethylpyrazine Nitrone - Guangzhou Magpie Pharmaceuticals

Next Previous
X
Search
Drug Profile

Tetramethylpyrazine Nitrone - Guangzhou Magpie Pharmaceuticals

Alternative Names: Nitoxazine - Guangzhou Magpie Pharmaceutical; Nitrazine - Guangzhou Magpie Pharmaceutical; TBN

Latest Information Update: 06 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jinan University
  • Developer Guangzhou Magpie Pharmaceuticals
  • Class Alkaloids; Anti-ischaemics; Eye disorder therapies; Neuroprotectants; Small molecules; Vascular disorder therapies
  • Mechanism of Action Brain derived neurotrophic factor agonists; Calcium channel antagonists; Cyclic AMP response element-binding protein stimulants; Free radical scavengers; MTOR protein inhibitors; Proto-oncogene protein c-akt modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Stroke
  • Phase II Amyotrophic lateral sclerosis; Diabetic nephropathies

Most Recent Events

  • 01 Aug 2024 Phase-III clinical trials in Stroke (IV) before August 2024 (Guangzhou Magpie Pharmaceuticals pipeline, August 2024)
  • 15 Oct 2023 Efficacy and safety data from a phase II trial in Amyotrophic lateral sclerosis released by Guangzhou Magpie Pharmaceuticals
  • 15 Oct 2023 Guangzhou Magpie Pharmaceuticals completes a phase II trial in Amyotrophic lateral sclerosis in China

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top